Manuel Sturzbecher-Hoehne

Head of CMC & Radiopharmaceutical Development Ariceum Therapeutics

Seminars

Tuesday 11th November 2025
Optimising Isotope Selection for Scalable Radiopharmaceutical Commercialisation
4:00 pm
  • Evaluating isotope availability, production capacity, and logistics for reliable clinical and commercial use
  • Aligning isotope half-life, emission type, and energy with therapeutic goals and pharmacokinetics
  • Addressing regulatory, technical, and cost considerations for efficient scale-up and market readiness
Manuel Sturzbecher Hohne, Head of CMC & Radiopharmaceutical Development, Ariceum Therapeutics